How Did Fisher & Paykel Healthcare (ASX:FPH), Ansell (ASX:ANN), and Clinuvel Pharmaceuticals (ASX:CUV) Perform on 5 November 2026?

Sonal Goyal

05 November 2026 06:16 PM AEDT

How Did Fisher & Paykel Healthcare (ASX:FPH), Ansell (ASX:ANN), and Clinuvel Pharmaceuticals (ASX:CUV) Perform on 5 November 2026?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Fisher & Paykel Healthcare (ASX:FPH) closed at A$38.89, up 4.32%, as the company provided first-half FY27 guidance and updated its full-year outlook.

• Ansell (ASX:ANN) closed at A$45.52, gaining 4.40%, following FY26 full-year results that showed Earnings growth in dynamic market conditions.

• Clinuvel Pharmaceuticals (ASX:CUV) closed at A$7.74, surging 9.32%, after filing its NEURACTHEL product submission to European regulatory agencies.

The S&P/ASX 200 (XJO) closed at 9,065.10 on 5 November 2026, up 2.61% or 230.60 points, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, adding 1,240.30 points to close at 35,329.10. Overnight Wall Street gains following the Democrats' decisive midterm election victory provided a tailwind for global Equity markets. Three specialty healthcare companies — Fisher & Paykel Healthcare Corporation Ltd (ASX:FPH), Ansell Ltd (ASX:ANN), and Clinuvel Pharmaceuticals Ltd (ASX:CUV) — each outperformed the broader market on the session.

Fisher & Paykel Healthcare — Guidance Update and Land Sale

Fisher & Paykel Healthcare Corporation Ltd (ASX:FPH), a New Zealand-based manufacturer of respiratory care devices and hospital products, closed at A$38.89, up 4.32%. The company provided first-half FY27 guidance and updated its full-year outlook on 21 August 2026, reflecting continued Demand for its hospital and homecare respiratory products.

Fisher & Paykel Healthcare designs and manufactures devices including nasal high flow therapy systems, humidification systems, and masks for use in hospital and home settings. The company operates Manufacturing facilities in New Zealand and Mexico and sells its products across more than 120 countries. In a separate announcement on 5 October 2026, the company disclosed an agreement to sell 13 hectares of its 105-hectare Drury site to Health New Zealand for the development of a new hospital, a transaction that will also support infrastructure development near its manufacturing campus.

Ansell — FY26 Earnings Growth Delivered

Ansell Ltd (ASX:ANN), a global leader in safety solutions, closed at A$45.52, up 4.40%. The company reported its FY26 full-year results on 24 August 2026, delivering sales and earnings growth in what management described as dynamic market conditions.

Ansell designs and manufactures personal protective equipment including industrial gloves, surgical gloves, and body protection products. The company operates across two segments: Healthcare, serving surgical and examination markets; and Industrial, providing hand and body protection for manufacturing, automotive, and chemical sectors globally. The FY26 result reflected Volume growth across both segments and ongoing cost management initiatives. Ansell has a global manufacturing footprint and supplies products to customers in more than 100 countries.

Clinuvel Pharmaceuticals — NEURACTHEL Filing in Europe

Clinuvel Pharmaceuticals Ltd (ASX:CUV), a biopharmaceutical company focused on photomedicine, closed at A$7.74, surging 9.32%. The company announced the filing of its NEURACTHEL product dossier to European regulatory agencies, marking a milestone in the expansion of its product portfolio.

Clinuvel's approved product, SCENESSE (afamelanotide), is used for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP), a rare genetic condition that causes severe light sensitivity. NEURACTHEL represents a new ACTH-based product that the company is seeking to bring to market in Europe. Clinuvel operates in a niche therapeutic area with limited competition, and its regulatory filings have the potential to expand its addressable market. The company has a global distribution network serving patients with rare skin conditions.

Sector Context

Fisher & Paykel Healthcare, Ansell, and Clinuvel each operate in distinct niches within the broader healthcare sector. Fisher & Paykel's respiratory devices serve a global hospital and homecare market driven by respiratory disease prevalence and ageing demographics. Ansell's protective equipment addresses workplace safety regulations across industrial and healthcare settings. Clinuvel occupies a rare disease niche with high barriers to entry and limited competitive pressure. The XHJ's 3.64% gain on 5 November 2026 supported all three names, with each outperforming the broader index.

The Outlook

All three specialty healthcare companies posted gains above the broader market on 5 November 2026. Clinuvel's 9.32% advance was the most notable, driven by its NEURACTHEL regulatory filing. Fisher & Paykel Healthcare's 4.32% gain reflected its guidance updates and strategic land transaction, while Ansell's 4.40% rise followed its FY26 earnings delivery. Each company benefits from global market exposure and differentiated product portfolios within their respective healthcare niches.

FAQs

Q: What does Fisher & Paykel Healthcare manufacture?

A: Fisher & Paykel Healthcare designs and manufactures respiratory care devices including nasal high flow therapy systems, humidification systems, and masks for hospital and homecare use.

Q: What are Ansell's two business segments?

A: Ansell operates Healthcare (surgical and examination gloves) and Industrial (hand and body protection for manufacturing, automotive, and chemical industries) segments globally.

Q: What is Clinuvel's NEURACTHEL product?

A: NEURACTHEL is an ACTH-based product that Clinuvel has submitted to European regulatory agencies, representing an expansion of its product portfolio beyond its existing SCENESSE treatment for EPP.

Q: Why did Clinuvel surge 9.32% on 5 November?

A: Clinuvel's gain followed the company's announcement of its NEURACTHEL product filing to European regulatory agencies, which represents a potential new revenue stream for the company.

Q: How did the ASX healthcare sector perform on 5 November 2026?

A: The S&P/ASX 200 Health Care index (XHJ) gained 3.64% to 35,329.10, adding 1,240.30 points, and outperforming the S&P/ASX 200 which rose 2.61%.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.